Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2009

Conditions

HCV Infection

Interventions

DRUG

ABT-450

capsules, QD or BID, 14 days, ascending doses

DRUG

ritonavir

capsules, QD or BID, 14 days, ascending doses

DRUG

Placebo for ABT-450

capsule, QD or BID, 14 days

DRUG

Placebo for ritonavir

capsule, QD or BID, 14 days

Trial Locations (1)

Site Reference ID/Investigator# 18161, Waukegan